.jpg)
2 hours ago
3
Article content
Expansion builds on successful collaboration across Latin America and reinforces commitment to advancing innovative cardiometabolic therapies across international markets
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Abu Dhabi, United Arab Emirates and Seoul, South Korea, June 29, 2026 (GLOBE NEWSWIRE) — Arcera Life Sciences (“Arcera”), a global life sciences company focused on advancing innovative and sustainable healthcare solutions, and Daewoong Pharmaceutical Co., Ltd. (“Daewoong”), a leading South Korean pharmaceutical company, today announced the expansion of their strategic partnership for Enavogliflozin, Daewoong’s novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, into key markets across the Middle East.
Article content
Article content
Article content
The agreement builds upon the successful collaboration established between Daewoong and M8 Pharmaceuticals for Latin America, a partnership that became part of the Arcera platform following Arcera’s integration of M8 in December 2024. Since then, Arcera and Daewoong have continued to strengthen their relationship, most recently achieving a significant milestone with the approval of Enavogliflozin in Mexico.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
The expansion into the Middle East represents the next phase of the partnership and reflects both companies’ shared commitment to increasing patient access to innovative therapies for people living with type 2 diabetes and related cardiometabolic conditions across emerging markets.
Article content
Enavogliflozin is a novel SGLT2 inhibitor developed by Daewoong and approved in South Korea for the treatment of type 2 diabetes mellitus. The therapy has demonstrated meaningful efficacy in glycemic control and represents an important addition to the growing range of treatment options available to patients and healthcare professionals globally.
Article content
Strengthening a Strategic Partnership Across Regions
Article content
Article content
The partnership expansion highlights Arcera’s ability to leverage relationships, capabilities, and expertise across its integrated global platform, creating opportunities beyond the original scope of acquired businesses.
Article content
By combining Daewoong’s innovative R&D capabilities with Arcera’s extensive regulatory, market access, and commercial infrastructure across international markets, the collaboration aims to accelerate access to innovative therapies in regions where patient needs continue to evolve. In the Middle East, cardiometabolic health remains an important healthcare priority and diabetes prevalence is among the highest in the world.
Article content
Isabel Afonso, Chief Executive Officer, Arcera said:
“At Arcera, we are building a leading life sciences company that connects innovation with patients across international markets. The expansion of our relationship with Daewoong reflects the strength of our business and demonstrates how we can create value by building long-term strategic partnerships that extend across multiple regions and therapeutic areas.”
English (US)